APOC3 and diabetes mellitus: Strengths of this study include the use of two distinct mouse models of diabetes to increase scientific rigor, and, similar to therapeutics considered for human cardiovascular outcome trials, use of liver-targeted APOC3 and ANGPTL3 GalNAc ASOs.